Clinical Trials Directory

Trials / Conditions / Urothelial Carcinoma Recurrent

Urothelial Carcinoma Recurrent

12 registered clinical trials studyying Urothelial Carcinoma Recurrent — 6 currently recruiting.

StatusTrialSponsorPhase
WithdrawnA Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Blad
NCT07342517
Relmada Therapeutics, Inc.Phase 3
Not Yet RecruitingA Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder C
NCT07464145
Relmada Therapeutics, Inc.Phase 3
RecruitingPhase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced
NCT07241793
Sun Yat-sen UniversityPhase 2
RecruitingClinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial C
NCT06983210
Nagoya UniversityPhase 2
Recruiting9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
NCT06823427
Mabwell (Shanghai) Bioscience Co., Ltd.Phase 2
RecruitingEvaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle
NCT05037279
Verity Pharmaceuticals Inc.Phase 3
RecruitinguTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
NCT05874921
UroGen Pharma Ltd.—
CompletedA Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB
NCT05375903
UroGen Pharma Ltd.Phase 1
UnknownEn Bloc TURBT With Collins Loop vs Conventional TURBT
NCT05027412
Hospital Universitario de FuenlabradaN/A
CompletedA Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk
NCT03914794
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2
WithdrawnVactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
NCT04064190
MedPacto, Inc.Phase 2
AvailableNamed Patient Program for Mitomycin for Pyelocalyceal Solution
NCT05494411
UroGen Pharma Ltd.—